At Myopia Centre, we only use evidence-based proven treatment to manage myopia. Evidence-based treatment includes the widely used atropine drops and dual-focus contact lenses such as MIsight.

One of the treatments of myopia is atropine eye drops. Many studies have shown a significant rate in slowing down the progression of myopia in children and their use is gaining popularity. It is one of the more effective methods to slow down the progression with little side effect.

Young children of age six to eight years old with myopia are more prone to rapid progression. Atropine eye drop slows down the progression of myopia in about 50% to 60% of children for low-dose atropine 0.01%, and 20% to 30% of children may require higher dose atropine (0.125% / 1%). 

However, myopia progression may still occur in some children, and if rapid, they may then need to be converted to a higher dose of atropine. Unfortunately, in 10% of children, myopia may continue to progress rapidly even with the higher-dose atropine.

Atropine treatment requires patients to be committed and motivated. Results from atropine may take time to show results therefore it will require close monitoring half yearly. The treatment regimen requires patients or parents to administer one drop of 0.01% atropine, daily, in each eye.

MIsight is a dual-focus myopia control 1-day soft contact lens that reduces the rate of progression. Lens provides clear vision at distance, intermediate and near vision while the peripheral treatment zones of the lens creates myopic retinal defocus that has been shown to control the rate of progression of myopia. This "peripheral defocus" may reduce the tendency for greater lengthening of the eye that leads to progressive myopia. A 4-year study has shown to slow down myopia progression and elongation of eye.